Warburtons puts $650K into new Cereals Canada HQ
Warburtons announced on Thursday its contribution to the capital campaign for the Global Agriculture Technology Exchange. Referred to as 'Gate' for short, the facility will help grain producers and processors bolster their international profiles and find new trading partners in response to U.S. tariffs and protectionism.
The U.K. brand sources 'significant volumes' of Canadian wheat from Western Canada and has been working with Canadian farmers and Cereals Canada for many years, campaign chair JoAnne Buth said in a news release.
MIKAELA MACKENZIE / FREE PRESS FILES
Various cereal grains on display at the Cereals Canada lab. United Kingdom bakery brand Warburtons has contributed $650,000 to a new Cereals Canada facility planned for Winnipeg's Exchange District.
Warburtons employees utilize Cereals Canada's pilot bakery, mill and lab to test and analyze Canadian wheat before it goes to the U.K. for production.
To date, the Gate capital campaign has raised $32 million toward its goal of approximately $100 million.
Monday Mornings
The latest local business news and a lookahead to the coming week.
The campaign is targeting contributions from industry groups, agribusinesses and individuals, and support from the three levels of government.
— Free Press staff
Aaron EppReporter
Aaron Epp reports on business for the Free Press. After freelancing for the paper for a decade, he joined the staff full-time in 2024. He was previously the associate editor at Canadian Mennonite. Read more about Aaron.
Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber.
Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Sun
10 minutes ago
- Toronto Sun
Joly: Visits to Saab, Lockheed 'normal' part of her job amid F-35 review
OTTAWA — Industry Minister Melanie Joly says Canadians shouldn't read too much into her visit to a Swedish defence manufacturer that comes right in the middle of a major government review of the F-35 fighter jet procurement. This advertisement has not loaded yet, but your article continues below. Create an account or sign in to continue with your reading experience. Create an account or sign in to continue with your reading experience. Subscribe now to read the latest news in your city and across Canada. Subscribe now to read the latest news in your city and across Canada. Joly says she visited Saab's facilities in Sweden this week and was shown the Gripen-E jet, which is one of the possible contenders to replace the controversial U.S.-made F-35 fighter jet. Article content Prime Minister Mark Carney ordered the review shortly after he became prime minister in March, as Canada sought tighter security and defence ties with Europe in response to U.S. President Donald Trump's trade war. The review is to be completed by the end of the summer and Joly says her role in it is to ensure the Canadian government understands all its options and what the industrial benefits to Canada would be in its final decision. Joly says this is a 'normal' part of her job, and that she will also be meeting with Lockheed Martin, which makes the F-35, in the coming weeks. Joly is wrapping up a trip to Sweden and Finland with Secretary of State for Defence Stephen Fuhr, which was focused on strengthening defence-industrial ties in Europe.
Winnipeg Free Press
10 minutes ago
- Winnipeg Free Press
Joly: Visits to Saab, Lockheed ‘normal' part of her job amid F-35 review
OTTAWA – Industry Minister Mélanie Joly says Canadians shouldn't read too much into her visit to a Swedish defence manufacturer that comes right in the middle of a major government review of the F-35 fighter jet procurement. Joly says she visited Saab's facilities in Sweden this week and was shown the Gripen-E jet, which is one of the possible contenders to replace the controversial U.S.-made F-35 fighter jet. Prime Minister Mark Carney ordered the review shortly after he became prime minister in March, as Canada sought tighter security and defence ties with Europe in response to U.S. President Donald Trump's trade war. The review is to be completed by the end of the summer and Joly says her role in it is to ensure the Canadian government understands all its options and what the industrial benefits to Canada would be in its final decision. Joly says this is a 'normal' part of her job, and that she will also be meeting with Lockheed Martin, which makes the F-35, in the coming weeks. Monday Mornings The latest local business news and a lookahead to the coming week. Joly is wrapping up a trip to Sweden and Finland with Secretary of State for Defence Stephen Fuhr, which was focused on strengthening defence-industrial ties in Europe. This report by The Canadian Press was first published Aug. 20, 2025.
The Market Online
an hour ago
- The Market Online
Ocumetics stock continues to climb after bionic lens implant
Shares of Ocumetics Technology (TSXV:OTC) are up by almost 400 per cent following Monday's announcement of a historical milestone: the first-in-human implant of a bionic intraocular lens Ocumetics is a Canadian research and product development company focused on vision-correction solutions Ocumetics stock has added 464.52 per cent year-over-year Shares of Ocumetics Technology (TSXV:OTC) are up by almost 400 per cent following Monday's announcement of a historical milestone: the first-in-human implant of a bionic intraocular lens. This content has been prepared as part of a partnership with Ocumetics Technology Corp., and is intended for informational purposes only. Unlike traditional monofocal or multifocal lenses, the Ocumetics Lens is designed to work with the natural movements of the eye, allowing the user to see clearly close up and at a distance without glasses or contacts following cataract surgery. The successful procedure is an important step in the drive to restore dynamic vision, with initial post-operative results expected in the coming weeks and additional implants planned under the clinical trial program over the coming months. Leadership insights 'This is a moment of immense pride for our team and everyone who has believed in Ocumetics from the beginning,' Dean Burns, Ocumetics Technology's president and chief executive officer, stated in Monday's news release. 'For nearly two decades, we've been focused on a bold vision, one that many thought was out of reach. Our scientists, engineers, clinical advisors and partners have poured their hearts into this innovation. Today we celebrate this success, but we know the work is far from done. There are millions of people waiting for us to get the Ocumetics Lens to market, and we are more driven than ever to bring this solution to the world.' 'The Ocumetics accommodating intraocular lens has the potential to reshape the global standard of care first for cataract, and eventually, presbyopia patients,' Burns added. 'This milestone reinforces Ocumetics' position as a leader in the next generation of ophthalmic innovation. With aging populations around the globe demanding better vision solutions, the potential impact of the Ocumetics Lens is profound.' About Ocumetics Technology Ocumetics is a Canadian research and product development company focused on vision-correction solutions, including an intraocular lens that fits within the eye's natural lens compartment. Ocumetics stock (TSXV:OTC) is up by 75 per cent trading at C$1.75 as of 10:51 am ET. The stock has added 464.52 per cent year-over-year. Join the discussion: Find out what investors are saying about this Canadian healthcare technology stock on the Ocumetics Technology Corp. Bullboard, and make sure to explore the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
